Five-Year Survival Results from the Remodl-B Trial (ISRCTN 51837425) Show Improved Outcomes in Diffuse Large B-Cell Lymphoma Molecular Subgroups from the Addition of Bortezomib to R-CHOP Chemoimmunotherapy-Reference-Cited by-同舟云学术

Five-Year Survival Results from the Remodl-B Trial (ISRCTN 51837425) Show Improved Outcomes in Diffuse Large B-Cell Lymphoma Molecular Subgroups from the Addition of Bortezomib to R-CHOP Chemoimmunotherapy

Published:2022-11-15 Issue:Supplement 1 Volume:140 Page:1770-1772
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Davies Andrew J¹,Stanton Louise²,Caddy Josh²,Barrans Sharon³,Wilding Sam⁴,Saunders Geoff N²,Mamot Christoph⁵⁶,Novak Urban⁷⁶,McMillan Andrew K.⁸,Fields Paul A⁹,Collins Graham P.¹⁰,Stephens Richard¹¹,Cucco Francesco¹²,Sha Chulin¹³,Van Hoppe Moniek³,Tooze Reuben M³,Care Matthew A¹⁴,Griffiths Gareth²,Schuh Anna¹⁵,Du Ming-Qing¹²,Westhead David R¹⁴,Burton Cathy³,Johnson Peter¹⁶

Affiliation:

1. 1CRUK Experimental Cancer Medicines Centre, University of Southampton, Southampton, United Kingdom

2. 2Cancer Research UK Southampton Clinical Trials Unit, University of Southampton, Southampton, United Kingdom

3. 3Haematological Malignancy Diagnostic Service, Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

4. 4CRUK Southampton Clinical Trials Unit, University of Southampton, Southampton, United Kingdom

5. 5Medical Oncology, Cantonal Hospital Aarau, Switzerland

6. 6The Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland

7. 7Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland

8. 8Department of Haematology, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom

9. 9Department of Haematology, Guy's and St. Thomas' NHS Foundation Trust, Kings Health Partners, London, United Kingdom

10. 10Department of Clinical Haematology, Oxford University Hospitals, Oxford, United Kingdom

11. 11Patient Representative, NCRI Consumer Forum, London, United Kingdom

12. 12Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge, United Kingdom

13. 13Institute of Basic Medicine and Cancer, Chinese Academy of Sciences, Hangzhou, China

14. 14School of Molecular and Cellular Biology and Leeds Institute of Data Analytics, University of Leeds, Leeds, United Kingdom

15. 15Department of Oncology, University of Oxford, Oxford, United Kingdom

16. 16Cancer Research UK Experimental Cancer Medicines Centre UK, Southampton, United Kingdom

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A phase 1-2 trial of DA-EPOCH-R plus ixazomib for MYC-aberrant lymphoid malignancies: the DACIPHOR regimen;Blood Advances;2024-03-27

2. Adding a Gene Expression Profile Test to Aid Differential Diagnosis and Treatment in Aggressive Large B-Cell Lymphoma: An Early Exploratory Economic Evaluation;Applied Health Economics and Health Policy;2023-11-28

3. Editorial: The molecular landscape and promising therapeutic targets in aggressive B-cell non-Hodgkin lymphomas;Frontiers in Oncology;2023-08-30

4. Diffuse large B‐cell lymphoma;Hematological Oncology;2023-07-12

5. A prognostic model based on gene expression parameters predicts a better response to bortezomib-containing immunochemotherapy in diffuse large B-cell lymphoma;Frontiers in Oncology;2023-04-28